[{"indications": "Indications\u00a0chronic severe spasticity resulting\r\nfrom disorders such as multiple sclerosis or traumatic partial section\r\nof spinal cord", "name": "BACLOFEN", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "10 Musculoskeletal and joint diseases", "10.2 Drugs used in neuromuscular disorders", "10.2.2 Skeletal muscle relaxants"], "cautions": "Cautions\u00a0psychiatric illness, Parkinson\u2019s disease, cerebrovascular disease, elderly; respiratory impairment; epilepsy; history of peptic\r\nulcer (avoid oral route in active peptic\r\nulceration); diabetes; hypertonic bladder sphincter; avoid abrupt\r\nwithdrawal (risk of hyperactive state, may exacerbate\r\nspasticity, and precipitate autonomic dysfunction including hyperthermia,\r\npsychiatric reactions and convulsions, see also under Withdrawal below); interactions: Appendix 1 (muscle relaxants)Withdrawal\u00a0Serious side-effects can occur on abrupt\r\nwithdrawal; to minimise risk, discontinue by gradual dose reduction\r\nover at least 1\u20132 weeks (longer if symptoms occur)Driving\u00a0Drowsiness may affect performance\r\nof skilled tasks (e.g. driving); effects\r\nof alcohol enhanced", "side-effects": "Side-effects\u00a0gastro-intestinal disturbances, dry mouth; hypotension,\r\nrespiratory or cardiovascular depression; sedation, drowsiness, confusion,\r\ndizziness, ataxia, hallucinations, nightmares, headache, euphoria,\r\ninsomnia, depression, anxiety, agitation, tremor; seizure; urinary\r\ndisturbances; myalgia; visual disorders; rash, hyperhidrosis; rarely taste disturbances, abdominal pain, changes in hepatic\r\nfunction, paraesthesia, erectile dysfunction, dysarthria; very rarely hypothermia", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/5335.htm", "doses": ["By mouth, adult and child over 10 years, initially\r\n5\u00a0mg 3 times daily, gradually increased; usual maintenance dose up\r\nto 60\u00a0mg daily in divided doses (max. 100\u00a0mg daily); child 1\u20132 years, initially 300\u00a0micrograms/kg daily\r\nin 4 divided doses, increased gradually to usual maintenance dose\r\n0.75\u20132\u00a0mg/kg (max. 40\u00a0mg) daily in divided doses (or 10\u201320\u00a0mg daily in divided doses); child 2\u20136 years, initially 300\u00a0micrograms/kg daily in 4 divided doses,\r\nincreased gradually to usual maintenance dose of 0.75\u20132\u00a0mg/kg (max.\r\n40\u00a0mg) daily in divided doses (or 20\u201330\u00a0mg daily\r\nin divided doses); child 6\u20138 years,\r\ninitially 300\u00a0micrograms/kg daily in 4 divided doses, increased gradually\r\nto usual maintenance dose of 0.75\u20132\u00a0mg/kg (max. 40\u00a0mg) daily in divided\r\ndoses (or 30\u201340\u00a0mg daily in divided doses); child 8\u201310 years, initially 300\u00a0micrograms/kg daily\r\nin 4 divided doses, increased gradually to usual maintenance dose\r\nof 0.75\u20132\u00a0mg/kg (max. 60\u00a0mg) daily in divided doses", "Review treatment if no benefit within 6 weeks\r\nof achieving maximum dose", "By intrathecal injection, specialist\r\nuse only, severe chronic spasticity unresponsive to oral antispastic\r\ndrugs (or where side-effects of oral therapy unacceptable) or as alternative to ablative neurosurgical procedures, adult over 18 years, initial test dose 25\u201350\u00a0micrograms over at least 1 minute via catheter or lumbar puncture,\r\nincreased in 25-microgram steps (not more often than every 24 hours)\r\nto max. 100\u00a0micrograms to determine appropriate dose, then\r\ndose-titration phase, most often using infusion pump (implanted\r\ninto chest wall or abdominal wall tissues) to establish maintenance\r\ndose (ranging from 12\u00a0micrograms to 2\u00a0mg daily for spasticity\r\nof spinal origin or 22\u00a0micrograms to 1.4\u00a0mg daily\r\nfor spasticity of cerebral origin) retaining some spasticity to avoid\r\nsensation of paralysis; child 4\u201318\r\nyears (spasticity of cerebral or spinal origin only), initial test dose 25\u201350\u00a0micrograms then titrated as for adult, initial maintenance dose 25\u2013200\u00a0micrograms\r\ndaily, adjusted according to response", "Consult product literature\r\nfor details on test dose and titration\u2014important to monitor patients closely in appropriately equipped and staffed environment\r\nduring screening and immediately after pump implantation. Resuscitation equipment must be available for immediate\r\nuse"], "pregnancy": "Pregnancy\u00a0manufacturer advises use only if potential benefit\r\noutweighs risk (toxicity in animal studies)"}]